Chris Senner News Today

Exelixis, Inc. misses on earnings expectations. Reported EPS is $0.17 EPS, expectations were $0.28.

EXEL earnings call for the period ending March 31, 2024.

EXEL earnings call for the period ending December 31, 2023.

- Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023 -- Cabozantinib Franchise Achieved $1,629 million in U.S. Net Product Revenues for the Fiscal Year 2023, including $429 million for the Fourth Quarter of 2023 -- GAAP Diluted EPS of $0.27 for the Fourth Quarter o...

Exelixis, Inc. (NASDAQ:EXEL) Q4 2023 Earnings Call Transcript February 6, 2024 Exelixis, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results Conference […]

- Total Revenues of $471.9 million, Cabozantinib Franchise U.S. Net Product Revenues of $426.5 million -- Conference Call and Webcast Today at 5:00 PM Eastern Time -ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2023 and provided an update on...

EXEL earnings call for the period ending September 30, 2023.

EXEL earnings call for the period ending June 30, 2023.

Operator: Good day, ladies and gentlemen, and welcome to the Exelixis Secod Quarter 2023 Financial Results Conference Call. My name is Tawanda and Ill be your operator for today.

EXEL earnings call for the period ending March 31, 2023.